
Car t cells drive out b cells in sle
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:

Access through your institution Buy or subscribe B cell depletion is an effective approach for the treatment of several diseases, including rheumatoid arthritis (RA); however, despite
showing initial promise in the treatment of systemic lupus erythematosus (SLE), the B cell depleting anti-CD20 antibody rituximab did not reach the clinical endpoints in two large phase III
clinical trials. Almost a decade later, a promising new approach to B cell depletion in SLE is emerging: CD19-targeted chimeric antigen receptor (CAR) T cell therapy. Unlike a standard CAR T
cell approach, the researchers used purified CD8+ T cells to avoid any potential disease-promoting effects that might come from using CD4+ T cells. As a second generation CAR, the CD3ζ C
terminus had been modified to dampen its activity and prevent T cell exhaustion (increasing the persistence of this therapy). This is a preview of subscription content, access via your
institution RELEVANT ARTICLES Open Access articles citing this article. * CLINICAL DEVELOPMENT OF CAR T CELL THERAPY IN CHINA: 2020 UPDATE * Jianshu Wei * , Yelei Guo * … Weidong Han
_Cellular & Molecular Immunology_ Open Access 30 September 2020 ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our
best-value online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue
Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL
ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES ORIGINAL ARTICLE * Kansal, R. et al. Sustained B cell depletion by
CD19-targeted CAR T cells is a highly effective treatment for murine lupus. _Sci. Transl. Med._ 11, eaav1648 (2019) Article Google Scholar Download references AUTHOR INFORMATION AUTHORS
AND AFFILIATIONS * Nature Reviews Rheumatology http://www.nature.com/nrrheum/ Jessica McHugh Authors * Jessica McHugh View author publications You can also search for this author inPubMed
Google Scholar CORRESPONDING AUTHOR Correspondence to Jessica McHugh. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE McHugh, J. CAR T cells drive out B
cells in SLE. _Nat Rev Rheumatol_ 15, 249 (2019). https://doi.org/10.1038/s41584-019-0214-x Download citation * Published: 04 April 2019 * Issue Date: May 2019 * DOI:
https://doi.org/10.1038/s41584-019-0214-x SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not
currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative